Submissions for variant NM_000179.2(MSH6):c.1176T>A (p.Asp392Glu) (rs587779912)

Total submissions: 2

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
GeneDx	RCV000212647	SCV000149279	uncertain significance	not provided	2014-03-24	criteria provided, single submitter	clinical testing	This variant is denoted MSH6 c.1176T>A at the cDNA level, p.Asp392Glu (D392E) at the protein level, and results in the change of an Aspartic Acid to a Glutamic Acid (GAT>GAA). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. MSH6 Asp392Glu was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Since Aspartic Acid and Glutamic Acid share similar properties, this is considered a conservative amino acid substitution and is unlikely to affect protein integrity. MSH6 Asp392Glu occurs at a position that is well conserved across species and is not located in a known functional domain. In silico analyses predict that this variant is probably damaging to protein structure and function. Based on currently available information, it is unclear whether MSH6 Asp392Glu is pathogenic or benign. We consider it to be a variant of uncertain significance.Of note, two deleterious MSH6 mutations on opposite chromosomes (in trans) are expected to cause Congenital Mismatch Repair Deficiency syndrome (CMMR-D). Therefore, if the variants are in trans, and if this patient does not have CMMR-D, then at least one variant is likely benign. Parental or family testing could help determine whether the variants are in cis or trans.
Ambry Genetics	RCV000115370	SCV000186107	uncertain significance	Hereditary cancer-predisposing syndrome	2013-01-22	criteria provided, single submitter	clinical testing	Lines of evidence used in support of classification: Insufficient or conflicting evidence